Extended Dosing With Eltrombopag for Severe Aplastic Anemia

* INCLUSION CRITERIA: * Previous diagnosis of refractory severe aplastic anemia and following at least one treatment course of immunosuppression with a regimen containing antithymocyte globulin, alemtuzumab or cyclophosphamide. * One or more of the following three clinically-significant cytopenias: platelet count less than or equal to 30,000/micro L or platelet-transfusion-dependence (requiring at least 4 platelet transfusions in the 8 weeks prior to study entry); neutrophil count less than 500/micro L; hemoglobin less than 9.0 g/dL or red cell transfusion-dependence (requiring at least 4 units of PRBCs in the eight weeks prior to study entry) * Age greater than or equal to 2 years old * Weight \> 12 kg EXCLUSION CRITERIA: * Infection not adequately responding to appropriate therapy * Evidence of a clonal disorder on cytogenetics performed within 12 weeks of study entry. * Creatinine \> 2.5 mg/dL * Direct Bilirubin \> 2.0 mg/dL * SGOT or SGPT \>5 times the upper limit of normal * Hypersensitivity to eltrombopag or its components\<TAB\> * Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential * Unable to understand the investigational nature of the study or give informed consent * Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that…